Introduction
Many previous attempts to evaluate the growth conditions and requirements of BCP-ALL cells have focused on a short-term colony assay in semisolid medium or a 3-day thymidine incorporation assay. Early studies using these assays demonstrated that so-called low-molecular weight B cell growth factor (LMW-BCGF), derived from cultures of phytohemagglutininstimulated peripheral blood lymphocytes, stimulated colony formation and DNA synthesis of BCP-ALL cells. [1] [2] [3] More recently, studies with recombinant cytokines demonstrated that IL-3 and IL-7 added singly stimulate proliferation of leukemic cells in short-term cultures from some but not all BCP-ALL patients. [4] [5] [6] [7] [8] Significantly, all of these studies have found that, in the great majority of cases, there is no significant survival or proliferation of BCP-ALL cells in the absence of exogenous growth factors.
To date, the most successful culture system for maintaining long-term survival of BCP-ALL in vitro has utilized bone marrow-derived stromal cell layers. Campana and colleagues found that leukemic cells from over 80% of cases tested underwent apoptosis when cultured in medium alone, including cultures to which fetal-bovine serum was added; these cultures showed rapid loss of viable cells (Ͼ50% decrease within 72 h). In contrast, when these cells were cultured in the presence of stromal feeder layers, apoptosis was inhibited and, in some cases, survival could be prolonged for up to several months. [9] [10] [11] However, the identity of the cytokines responsible for this effect has not been definitively established. In contrast, several studies of normal human BCP-cells have shown that IL-7 and IL-3 stimulate their growth. Wolf et al 12 reported that proliferation of normal human BCP cells in bone marrow stroma-supported cultures was enhanced by addition of exogenous IL-7. Saeland et al 13 reported that IL-3 stimulated proliferation of normal BCP-cells in cultures with or without stromal cell support. Furthermore, the stimulatory effect of both IL-3 and IL-7 on normal BCP-cells was remarkably increased following activation of CD40 by anti-CD40 antibody. Moreover, utilizing a co-culture system (CD40 system) in which BCP cells were stimulated by anti-CD40 monoclonal antibody immobilized on Fc␥-receptor-transfected murine Ltk− cells, Larson et al 14 and Saeland et al 15 found that normal human BCP cells were uniquely responsive to IL-3 in the presence of anti-CD40, although provision of either IL-3 or anti-CD40 alone had no effect on BCP cell proliferation.
The CD40 antigen, a 50-kDa cell surface protein, is expressed on normal and neoplastic B cells, including BCP-ALL cells. [16] [17] [18] [19] [20] Stimulation of CD40 by either the CD40 ligand (CD40L) or anti-CD40 antibodies induces a potent activation signal in mature B cells 21, 22 characterized by expression of activation antigens, 23, 24 tyrosine kinase activity, 25 Ig class switching [26] [27] [28] and increased DNA synthesis. 29 The function of CD40 in early-B cell development, as well as the signals induced by activation of CD40 in BCP cells, are not well understood. In particular, the mechanisms by which CD40 activation plus IL-3 stimulates normal BCP cell proliferation remain unclear.
The functional activity of CD40 expressed on BCP-ALL cells has recently been studied by Renard et al. 30 They found that BCP-ALL cells can be induced to proliferate via the CD40 pathway in response to activated T cells, as detected by a short-term thymidine incorporation assay. However, this study did not examine whether proliferation of BCP-ALL cells in the CD40 pathway requires the presence of growth factors. Planken et al 20 reported that short-term proliferation of CD40 + BCP-ALL cells, as measured by thymidine incorporation, could be induced in most cases by crosslinking with CD40 antibody in the presence of IL-3. However, these investigators did not examine the ability of CD40L and other growth factors to support long-term proliferation of BCP-ALL cells.
In the present study, we evaluated the proliferation and survival of pediatric BCP-ALL cells in the presence of CD40L and cytokines (including IL-3, IL-7 and SCF) known to support proliferation of normal BCP cells. We found that CD40L plus IL-3 significantly increased the proliferation of BCP-ALL cells in serum-free cultures, and long-term growth (Ͼ8 weeks) of these cells from some patients could be maintained in cultures with CD40L and IL-3 in the presence of either SCF or IL-7. Importantly, we have found that CD40L strongly enhances expression of IL-3 receptors and induces lower-level upregulation of receptors for IL-7 and stem cell factor (c-Kit) on these cells, thereby sensitizing them to the proliferative effects of the corresponding factors.
Materials and methods

Cells
Bone marrow (BM) samples were studied from a total of 16 pediatric patients (12 BCP-ALL, two T-ALL and two AML), diagnosed by standard morphological, immunologic, and cytochemical criteria. Mononuclear cells from BM were separated by Ficoll-Hypaque centrifugation (1.007 g/ml), and monocytes in ALL samples were removed by 1-h adherence to plastic. Specimens containing more than 90% blasts by immunophenotyping after Ficoll-Hypaque separation were included in the study. Purified leukemic blasts were used immediately or cryopreserved for later use. Continuously growing BCP-ALL cell lines (EU-1, EU-3 and EU-18) were established in our laboratory as described previously. 31 BCP-ALL cells from seven of 12 patients were studied for proliferation and growth in long-term cultures. The clinical and laboratory characteristics of these seven patients, including immunophenotype, karyotype and IGH gene rearrangement, are summarized in Table 1 . BCP-ALL cells from these patients were further purified with anti-CD19 monoclonal antibody and magnetic immunobeads. Cells were stained with anti-CD19 (Pharmingen, San Diego, CA, USA) at 4°C for 30 min, washed, and then incubated for 30 min with magnetic immunobeads coated with rabbit anti-mouse antibody (Dynabeads M-450, Dynal, Oslo, Norway). Bead-rosetted cells were separated with a magnet and incubated overnight to allow beads to detach. Sorted cells were at least 99% CD19 + , as determined by fluorescence microscopy, and viability (by trypan blue) was at least 90%.
Cytokines and monoclonal antibodies
CD40L, IL-7 and SCF were provided by Immunex (Seattle, WA, USA), and IL-3 was purchased from Promega (Madison, 
Western blot assay
Purified primary bone marrow leukemic cells and cell lines before and after treatment with CD40L were lysed in a buffer composed of 150 mm NaCl, 50 mm Tris (pH 8.0), 5mm EDTA, 1% (v/v) Nonidet p-40, 1 mm phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and 25 g/ml leupeptin for 30 min at 4°C. After clarification, equal amounts of protein extracts were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose paper. After blocking with buffer containing 20 mm Tris-HCl (pH 7.5) and 500 mm NaCl/5% non-fat milk for 1 h at room temperature, the filter was incubated with specific antibody to IL-3R for 1 h at room temperature, followed by HRP-labelled secondary antibody. Blots were developed using a chemiluminescent detection system (ECL, Amersham Life Science, Buckinghamshire, England). After stripping, the filter was repeatedly probed with anti-IL-7R, anti-c-Kit antibodies and an antiactin antibody as a control for equal protein loading and protein integrity.
Proliferation assay
Cell proliferation was measured by DNA synthesis assay. Cells were incubated in 96-well flat-bottom plates (1 × 10 5 cells per well) in serum-free AIM-V lymphocyte culture medium (GibcoBRL, Grand Island, NY, USA). Cytokines and antibodies were added or withdrawn as described. Experiments were performed in triplicate. Freshly obtained or thawed cells were incubated for 48 h, and then 0.5 Ci tritiated thymidine was added per well. Cells were incubated for another 24 h and then harvested on glass-fiber filters using a cell harvester. Filters were dried, and thymidine incorporation was measured by liquid scintillation spectrometry.
Cell culture experiments
Cultures of purified CD19
+ BCP-ALL cells were performed in AIM-V lymphocyte culture medium. Cells were cultured at an /ml in 6-well plates with the addition of CD40L, IL-3, SCF and IL-7 either alone or in various combinations. Cultures were maintained in 5% CO 2 inair at 37°C, and cells were fed every 3 to 4 days by adding fresh medium and cytokines to maintain cell concentration at approximately 2-4 × 10 6 /ml. In cultures without apparent cell expansion, the cells were fed every 7 days by replacing 50% of the supernatant with fresh medium and additives. The total number of cells in each culture was calculated by counting the viable cells every week. Additionally, cytokine-withdrawal experiments were performed with cells from UPN 7 to identify minimal requirements of BCP-ALL growth. After washing, cells were recultured in medium in the absence of one of the original cytokines, and proliferation was measured by DNA synthesis assay and viable-cell counts. Furthermore, neutralizing antibodies to IL-3R, IL-7R and c-Kit were added to cultures with CD40L + IL-3 + SCF + IL-7, and the effect of these antibodies on cell proliferation was assessed by thymidine incorporation assay.
Immunophenotyping
Phenotypic analysis of cells pre-and post-culture was performed using standard procedures. Briefly, cells were washed in PBS containing 0.2% BSA before incubation with FITC-or PE-conjugated monoclonal antibodies: CD3, CD5, CD10, CD13, CD19, CD22, CD33, HLA-DR, SIg, cIgM and TdT. Isotype-matched, fluorochrome-conjugated nonreactive antibodies served as controls. After incubation at 4°C for 30 min, cells were washed, resuspended in PBS containing 0.2% sodium azide, and analyzed with a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
DNA preparation and polymerase chain reaction
Genomic DNA for PCR was prepared from purified primary bone marrow leukemic cells before and after culture, using a DNA Isolation Kit (Puregene, Minneapolis, MN, USA) following the manufacturer's instructions. A single V H primer (5Ј-CTGTCGACACGGCCGTGTATTACTG-3Ј) homologous to a highly conserved sequence near the 3Ј-end of FR3 was used in conjunction with a single consensus J H primer (5Ј-AACTGCAGAGGAGACGGTGACC-3Ј) to amplify the IGH gene. This pair of primers can detect rearrangements involving the variable (V), diversity (D) and joining (J) regions of the IGH gene in 84% of clonal B cell specimens, as reported by Sioutos et al. 32 PCR amplification was performed in a 100 l reaction volume using 1 g of template DNA, 50 pmoles of each primer, 200 m of each dNTP, 10 mm TrisHCl (pH 8.3), 50 mm KCl, 1.5 mm MgCl 2 , 0.001% gelatin, and 2.5 U of Taq DNA polymerase. Following an initial denaturation step at 94°C for 5 min, 44 cycles of amplification were performed (denaturation at 94°C for 1.5 min/annealing at 59°C for 1.5 min/elongation at 72°C for 3 min), followed by a final elongation step of 5 min at 72°C. The amplified product was resolved by electrophoresis on 2% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light. With this assay, clonal IGH gene rearrangements (characteristic of B-lymphoid neoplastic proliferation) are evident as discrete bands, with a major band in the 90-160 bp range representing the primary rearrangement. 32 In contrast, normal polyclonal B-cell proliferation results in a smear rather than in discrete bands. In addition to these clonal bands, a band of approxiLeukemia mately 50 bp is typically seen in both monoclonal and polyclonal populations and represents annealing of the VH and JH primers (ie primer-dimers).
Results
Upregulation of receptors for IL3, IL7 and SCF by CD40L in BCP-ALL cells
We examined the expression of receptors for IL-3, IL-7 and SCF in 19 leukemia samples (12 BCP-ALL, two T-ALL, two AML and three BCP-ALL lines) before and after CD40L treatment by Western blot assay. A representative western blot of fresh BCP-ALL cells from seven patients is shown in Figure 1 . Pre-treatment, both freshly obtained and cryopreserved BCP-ALL cells had undetectable or very low levels of IL-3R, with the exception of UPN 5, whose leukemic cells expressed relatively high levels of IL-3R. After treatment with CD40L for 24 h, BCP-ALL cells from all 12 patients showed a 50 (UPN 5)-to 500 (UPN 6)-fold increase in IL-3R expression compared to controls. In kinetic studies of receptor expression, CD40L significantly upregulated IL-3R expression by UPN7 cells as early as 1 h after treatment. Expression of IL-7R and c-Kit was also induced by CD40L in 10/12 BCP-ALL cases examined; however, levels of induction were low (2-to 10-fold increase) compared to those for IL-3R (Figure 1 ). Cells cultured in medium alone resembled freshly obtained (pre-culture) cells in receptor expression and did not show induction of IL-3R, IL-7R or c-Kit (data not shown).
To evaluate whether significant upregulation of IL-3R by CD40L occurs uniquely in BCP-ALL cells, we examined fresh T-ALL and AML BM cells from two pediatric patients at diagnosis, respectively. Before treatment with CD40L, both T-ALL samples expressed IL-3R, and no or very low levels of IL-3R were detected in the two AML specimens. Upregulation of IL-3R by CD40L treatment was not observed in any of these cases (Figure 2) . Also, IL-3R was not significantly upregulated by CD40L in three BCP-ALL cell lines studied. In contrast, the original cryopreserved leukemic BM cells from which one of the three lines (EU-18) was derived showed striking upregulation of IL-3R by CD40L (Figure 2) .
Effect of CD40L and other cytokines on short-term proliferation by BCP-ALL cells
The response of BCP-ALL cells to CD40L, IL-3, SCF and IL-7 was analyzed in seven of the 12 BCP-ALL patients by thymidine incorporation assay. Table 2 shows the DNA-synthesis stimulation index (SI) for BCP-ALL cells cultured in serum-free medium with these cytokines. A proliferative response to CD40L alone (1.5-to 2.1-fold increase in SI) was observed in three of the seven cases studied (UPN 1, 2, 6 ). Response to either IL-3, SCF or IL-7 singly varied from case to case: proliferation of BCP-ALL cells from approximately one-third of the cases was stimulated (1.5-to 2.9-fold increase) by each cytokine singly, although significant interpatient differences were observed. For example, IL-7 but not IL-3 and SCF stimulated proliferation of BCP-ALL cells from UPN 1, whereas IL-3 but not IL-7 and SCF stimulated proliferation of cells from UPN 4. The proliferation of BCP-ALL cells from all seven patients studied was significantly increased when cultured with CD40L in combination with either single or multiple factors (Table 2) . Thymidine incorporation data for patient 7
Figure 1
Representative Western blot of IL-3R, IL-7R and c-Kit expression by primary BCP-ALL cells. Protein extracted from freshly isolated BCP-ALL cells (C) and BCP-ALL cells treated with CD40L (T) for indicated time (hours) was electrophoresed, transferred to nitrocellulose, and probed with anti-IL-3R antibody, followed by HRP-labelled secondary antibody. Blots were subsequently stripped and re-probed with anti-IL-7R, anti-C-Kit and anti-actin (as a control for equal protein loading and protein integrity).
Figure 2
Western blot analysis of IL-3R expression by primary non-BCP-ALL leukemic cells compared to BCP-ALL primary cells and cell lines following incubation with CD40L. Protein was extracted from primary T-ALL and AML BM cells and BCP-ALL cell lines (EU-1, EU-3 and EU-18) before (C) and after treatment (T) with CD40L for 24 h, and Western blot was performed as described in Figure 1 . Cryopreserved primary leukemic BM cells from which the EU-18 line was derived served as a positive control, since these cells show strong upregulation of IL-3R in the presence of CD40L. Media controls (cells cultured in serum-free Aim-V medium alone) resembled pre-culture cells in receptor expression (data not shown). (UPN7) are shown in Figure 3 : a 13-fold increase in proliferation was obtained when leukemic cells from this case were cultured with CD40L + IL-3 + SCF.
Long-term growth of BCP-ALL cells in the presence of CD40L and other cytokines
Formation of small spherical aggregates of cells could be detected after approximately 3 days culture with CD40L plus IL-3 alone or in combination with either SCF or IL-7 in all seven BCP-ALL cases studied, but not in control cultures lacking either CD40L or IL-3; Figure 4 illustrates the appearance of these clusters after 1 week. Long-term growth (Ͼ8 weeks) was obtained with CD40L + IL-3 + SCF with leukemic cells from three of the seven patients (UPN 2, 6 and 7). The proliferation of leukemic cells from UPN 7 in cultures with CD40L and different combinations of cytokines is shown in Figure 5 . There were no significant differences in cell expansion in cultures with CD40L + IL3 + SCF compared to those with these cytokines plus IL-7 (or with IL-7 substituted for SCF). In contrast, CD40L plus IL3 alone were not able to maintain longterm growth of BCP-ALL cells ( Figure 5 ). Overall expansion in
Figure 3
Effect of CD40L and various recombinant cytokines on the proliferation of BCP-ALL cells from patient 7 (UPN 7). Freshly isolated BCP-ALL cells (10 5 ) were cultured with medium alone (control) and with the indicated cytokines (CD40L, IL3, SCF and IL7 both singly and in combination) for 72 h. DNA synthesis was measured by 3 H-TdR uptake. Data represent mean c.p.m. ± s.d. for triplicate wells. Media controls (cells cultured in serum-free Aim-V medium alone) resembled pre-culture cells in receptor expression (data not shown).
Figure 4
Growth of CD19 + BCP-ALL cells cultured with CD40L plus IL-3 and SCF for several days. Micrograph (×400 original magnification) shows formation of spherical aggregates of BCP-ALL cells.
cell number was calculated to be approximately 25-fold for UPN 7 during the 10-week culture period; similar increases were seen in corresponding cultures performed with UPN 2 (24-fold increase) and UPN 6 (54-fold increase).
There was no evidence of cell proliferation (ie spherical aggregate formation or increased cell number) when BCP-ALL cells were cultured with single cytokines (either CD40L, IL3, SCF or IL-7) for up to 2 weeks. Although aggregate formation could be observed after several days in culture with combinations of CD40L and a single growth factor, the total cell number in these cultures was not significantly increased after 2 to 3 weeks.
To determine whether continued presence of individual cytokines was required to support long-term growth of BCP-ALL cells, we selectively eliminated cytokines from 8-week cultures established from patient 7 with CD40L + IL-3 + SCF.
As shown in Figure 6 , withdrawal of IL-3 significantly
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Figure 5
Comparison of growth rate for BCP-ALL cells in different culture conditions. Freshly isolated CD19
+ BCP-ALL cells from UPN 7 were cultured with CD40L plus IL-3 in serum-free (Aim-V) medium either with or without combined SCF and IL-7. Cultures were fed every 3 or 4 days. The total numbers of cells were calculated every week. Data represent numbers of viable cells recovered in triplicate cultures ± s.d.
Figure 6
Effect of withdrawal of cytokines on proliferation and growth of expanded BCP-ALL cells from UPN 7 in culture with CD40L + IL3 + SCF for 8 weeks. Cultured cells were washed and resuspended in serum-free culture medium without the indicated cytokines. Cell proliferation was measured by 3 H-TdR uptake assay after 72-h culture (a), and growth rate was determined by counting the viable cells every day for 7 days (b).
Figure 7
Effect of neutralizing anti-IL-3R, anti-IL-7R, and anti-c-Kit antibodies on the proliferation of long-term cultures of BCP-ALL cells. Leukemic cells from UPN 7 were cultured with CD40L + IL3 + SCF + IL7 for 8 weeks. Antibodies (including a mouse IgG1, control antibody) were added to the cultures every day at the indicated dose for 3 days, and cell proliferation subsequently determined by 3 H-TdR incorporation assay.
inhibited DNA synthesis and growth rate compared to withdrawal of either CD40L or SCF, which slightly suppressed proliferation. Furthermore, the requirement for IL-3 to maintain long-term growth of CD40-activated BCP-ALL cells was confirmed by experiments in which the IL-3 receptor was blocked with anti-IL-3R antibody. As shown in Figure 7 , addition of 1 g/ml of anti-IL-3R antibody to 8-week cultures of UPN 7 cells (cultured with all four cytokines) inhibited DNA synthesis up to 50%. In contrast, addition of either anti-c-Kit or anti-IL-7R antibodies had much less effect on proliferation.
Immunophenotypic and genotypic features of BCP-ALL cells in long-term cultures
To characterize cells in long-term (Ͼ2 months) cultures with CD40L plus IL-3 and SCF or IL-7, we examined their immunophenotype and IGH gene rearrangement to confirm that they represented the original leukemic clone. In all three cases, cultured cells were identical to the original cells in their expression of CD19 and CD10 (Figure 8 ). No T cell, myeloid cell on mature B cell markers such as CD5, CD33 and SIg were detected on these cells (data not shown). Furthermore, in all three cases with long-term growth, DNA was extracted simultaneously from cultured cells and cryopreserved leukemic BM cells for PCR analysis to examine IGH gene rearrangement. As shown in Figure 9 , cultured cells from all three cases (lanes 5, 7 and 9 for patients UPN 2, 6 and 7, respectively) showed IGH gene rearrangements identical to those of the original leukemic cells (lanes 4, 6 and 8, respectively). PCR amplification of DNA from UPN 2, 3 and 4 (lanes 10 and 11 for cases 3 and 4, respectively) produced a discrete band in the size range of 90-160 bp, while DNA from UPN 6 and 7 showed three discrete bands in both primary leukemic and cultured cells (two at 90-160 bp and one at approximately 500 bp), indicating the presence of up to three clonal IGH rearrangements (possibly representing clonal evolution in the leukemic population). IGH gene rearrangements were not detected in two (UPN 1 and 5 ) of the seven cases studied using this pair of primers. A smear but not a
Figure 9
Agarose gel analysis of PCR products for IGH rearrangements in BCP-ALL cells obtained before culture and after 2 months of culture. Lane 1, normal peripheral blood lymphocytes showing a smear, indicating polyclonality; lane 2, a BCP-ALL cell line (EU-1) used as a positive control and showing discrete bands indicating monoclonality; lane 3, a T-ALL cell line (KT) used as a negative control; lanes 4, 6, 8 10 and 11, cryopreserved leukemic BM cells (before culture) from UPN 2, 6, 7, 3 and 4, respectively; lanes 5, 7 and 9, long-term growing cells obtained from cultures with CD40L + IL-3 + SCF of UPN 2, 6 and 7, respectively. band was present in peripheral blood lymphocytes from a normal donor, indicating polyclonal IGH gene rearrangements characteristic of normal B cells. A 50 bp band faintly visible in all lanes represents annealing of the primers (primerdimers) not bound by cellular DNA; this band is stronger in the negative control (lane 3), which represents DNA from a T cell line lacking IGH rearrangements. These findings indicate that proliferating cells were derived from the leukemic clone and not from normal B cell precursors or mature B cells.
Discussion
Previous studies have shown that B-lineage ALL cells typically undergo rapid apoptosis and loss of viability when cultured in medium lacking exogenous growth factors, and addition of fetal-bovine serum alone is in most cases unable to sustain the survival or proliferation of these cells. Recombinant cytokines capable of supporting long-term BCP-ALL cell survival and proliferation in vitro have not been definitively identified, although certain combinations of cytokines are capable of stimulating short-term proliferation. [1] [2] [3] [4] [5] [6] [7] [8] [9] Interestingly, adherent, bone marrow-derived stromal cells (ie nonhematopoietic cells found in the bone marrow cavity, including endothelial and reticular cells, fibroblasts and adipocytes) can act as feeder layers for BCP-ALL cells, inhibiting apoptosis and extending survival of these cells even in the absence of serum. [9] [10] [11] Using stromal-cell cultures, Manabe et al 9, 10 reported that BCP-ALL cells from six of eight patients showed enhanced survival/proliferation; the number of CD19
+ leukemic cells recovered after 7 days culture ranged from 69 to 125% (median, 95%) of those seeded, compared to 0.3-16% (median, 0.7%) in cultures without stromal cells. Nishigaki et al 11 recently reported that a subset of leukemic cells from approximately 50% of BCP-ALL patients tested could proliferate in these cultures for up to several months. However, the identity of factors derived from these stromal cell cultures has not been reported. Although several cytokines including IL-7 and SCF are produced by stromal cells, neutralizing antibodies to IL-7 and SCF affected neither the survival nor proliferation of leukemic cells in the presence of stromas, suggesting that the cells were not dependent on these factors.
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Although previous studies have reported the presence of certain cytokine receptors such as IL-3R and IL-7R on B-lineage ALL cells, rIL-3 and IL-7 alone appear unable to significantly stimulate proliferation and growth of these cells in vitro, [5] [6] [7] possibly due to low levels of expression of these receptors. In our study, levels of IL-3R and IL-7R expression were very low in pre-activated BCP-ALL cells from most cases; therefore, proliferation of BCP-ALL cells in response to IL-3 or IL-7 was only detected by a sensitive thymidine incorporation assay in some cases, and the cells could not be maintained in long-term culture with IL-3 and/or IL-7 alone.
A significant finding of the present study is that CD40L was able to induce the expression of receptors for IL-3, IL-7 and SCF in BCP-ALL. In particular, CD40L was able to induce up to 500-fold increase in IL-3R expression. Furthermore, both CD40L and IL-3 were required to significantly stimulate shortterm proliferation of BCP-ALL cells, suggesting that upregulation of IL-3R by CD40 activation is essential for proliferation of these cells in vitro. Previous studies have demonstrated that the stimulatory effect of IL-3 on BCP-ALL cells is dependent on the level of IL-3R expression. 4 , 5 Uckun et al 5 found that IL-3 was able to stimulate the proliferation of leukemic cells from Leukemia five of 12 BCP-ALL patients, and there was a significant correlation between IL-3 binding and IL-3 responsiveness. In our study of seven BCP-ALL patients, only one case (UPN 5) expressed relatively high levels of IL-3R before stimulation with CD40L, and IL-3 significantly stimulated DNA synthesis in this case. However, activation of CD40 by CD40L strongly induced the expression of IL-3R on BCP-ALL cells from all patients studied, resulting in a marked proliferative response to recombinant IL-3.
CD40, a receptor belonging to the tumor necrosis factorreceptor superfamily, is expressed on normal and malignant B cell precursors, including leukemic cells from a significant number of pediatric BCP-ALL patients. [18] [19] [20] The percentage of CD40 + cells and expression level of antigen as detected by immunofluorescence varies among patients;
18-20 although we did not directly measure the intensity of CD40 expression, we found all cases tested were CD40 + using a functional assay (upregulation of IL-3R following incubation with CD40L), as well as by immunoblotting for CD40 protein (data not shown).
Our findings are consistent with those of Planken et al, 20 who reported that CD40 was expressed in all CD19 + BCP-ALL cases patients tested. Furthermore, these investigators reported that crosslinking of CD40 on these cells (either with an anti-CD40 antibody or by coculture with CD40L-transfected 3T6 fibroblasts) could stimulate DNA synthesis in short-term (7 day) cultures in the presence of IL-3 and fetal-bovine serum; in the present studies, cells were cultured in serum-free medium to further define their growth requirements in both short-and long-term cultures. Significantly, we were able to maintain short-term growth of BCP-ALL cells under defined growth conditions with CD40L and IL-3 alone; however, longterm proliferation (for at least 8 weeks from some cases) required SCF or IL-7 in addition to the above factors.
A similar effect of anti-CD40 antibody and IL-3 on proliferation and growth of normal BCP cells has been reported by several groups. [13] [14] [15] In these studies, IL-3 acted as a specific co-signal with anti-CD40 antibody for stimulating proliferation of normal BCP-cells, and proliferation was further enhanced by addition of IL-7 and IL-10. In the present study, addition of IL-7 to cultures with CD40L + IL-3 increased the proliferation and growth rate of BCP-ALL cells from some cases. Additionally, we found that SCF has a similar effect to IL-7 in enhancing the long-term proliferation and growth of BCP-ALL cells cultured with CD40L + IL-3.
Using immunophenotypic and genotypic analysis, we found that cells derived from long-term cultures with CD40L + IL3 + SCF or IL-7 resembled pre-culture BCP-ALL cells. Our results agree with those of Planken et al, 20 who found that CD40-activated BCP-ALL cells cultured for up to 1 week in IL-3 conserved their leukemic phenotype. In their study, no evidence for maturation and differentiation was found, and in pro-B cases, cells remained CD10-negative. In the present study, a polymerase chain reaction assay for rearrangement of the VDJ region of the IGH gene demonstrated that cells growing in long-term culture for 5-8 weeks were derived from the leukemic clone.
IL-7R and c-Kit (SCF-R) were also induced by CD40L in BCP-ALL cells from the majority of cases studied, although the post-induction levels of these two receptors were very low (2-to 4-fold increase) compared to IL-3R (50-to 500-fold increase). However, upregulation of c-Kit and IL-7R may be important in maintaining long-term growth of BCP-ALL in the presence of CD40L + IL-3, since cells cannot grow over 3 to 4 weeks without addition of SCF or IL-7, as seen in two cases. Our data suggest that CD40L stimulates IL-3R expression by the major population of BCP-ALL cells, enabling short-term proliferation (3-4 weeks) in the presence of IL-3. In contrast, CD40L apparently induces expression of IL-7R and c-Kit on a subset of leukemic cells, as indicated by the much lower levels of receptor expression. IL-7 and SCF, which are involved in proliferation of lympho-hematopoietic progenitors, 33 may stimulate the renewal capacity of a small population of neoplastic progenitors in the presence of CD40L and IL-3, resulting in long-term (Ͼ8 weeks) proliferation. Furthermore, IL-7 may induce the expression of CD40 on BCP-ALL cells and facilitate the binding of CD40L; we have observed increased expression of CD40 antigen on BCP-ALL cells cultured with IL-7 (unpublished data).
Upregulation of IL-3R by CD40L requires expression of CD40 antigen on the surface of primary BCP-ALL cells, since we did not observe any upregulation of IL-3R by CD40L in CD40-negative T-ALL and AML cases. CD40L failed to induce the expression of IL-3R in BCP-ALL cell lines due to the absence or very low levels of CD40 expression on these cells (unpublished data).
We failed to maintain long-term growth of BCP-ALL cells from four of the seven patients using CD40L plus IL-3 and SCF or IL-7, suggesting the heterogeneous nature of leukemic cells from BCP-ALL patients. Although CD19
+ BCP-ALL cells from these four patients responded to CD40L plus IL-3 by upregulating IL-3R and proliferating in short-term cultures, cell number did not expand after 3-to 4-weeks culture with these cytokines and either SCF or IL-7. The reason for failure of longterm growth of leukemia cells from these patients is unclear and will require analysis of further cases.
In conclusion, we report that CD40L strongly upregulates expression of IL-3R by BCP-ALL cells, and leukemic cells from a subset of patients showed long-term proliferation in the presence of CD40L + IL-3 + SCF or IL-7 under serum-free conditions. The proliferating BCP-ALL cells completely retained their original leukemic features including immunophenotype and monoclonal IGH gene rearrangement. CD40L induced the expression of receptors for cytokines, suggesting that the interaction of CD40 on BCP-ALL cells and CD40L (expressed primarily by T cells) may play an important role in the development and progression of disease. The ability to maintain long-term growth of BCP-ALL cells in defined media using CD40L and other cytokines should be useful in further studies of the cellular and molecular biology of BCP-ALL cells.
